Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- OPINION
April 10, 2006
- Janssen Pharm. Reports 7th Year of Double-Digit Growth
April 10, 2006
- HUMAN RESOURCES NEWS IN BRIEF
April 10, 2006
- Yoh Narimatsu Appointed President and CEO of Quintiles Japan
April 10, 2006
- MEDICAL DEVICE NEWS IN BRIEF
April 10, 2006
- BUSINESS NEWS IN BRIEF
April 10, 2006
- JMA
April 10, 2006
- FY2006 Budget Proposal Approved
April 10, 2006
- 39 of World's 99 Top-Selling Drugs Unapproved in Japan: Mr Wolf of PhRMA
April 10, 2006
- Korosho to Gear Up Steps to Eliminate Provisional Delivery
April 10, 2006
- Economist Conferences: 5th Roundtable on Healthcare Reform in Japan
April 10, 2006
- PMDA to Propose Policy Regarding Int'l Joint Clinical Trials
April 3, 2006
- Dispensing Fee Revision to Hit Major Dispensing Pharmacies: JPA
April 3, 2006
- Japan Should Participate in Global Trials from an Early Stage: Mr Mori of PMDA
April 3, 2006
- JPA's Top Priority Projects Outlined by Mr Ishii
April 3, 2006
- R&D NEWS IN BRIEF
April 3, 2006
- Hodanren Submits Petition on NHI Pricing, Medical Fees
April 3, 2006
- SEMINAR
April 3, 2006
- Meeting of Prefectural Pharm. Affairs Managers
April 3, 2006
- TeGenero's Investigational Antibody Drug Causes Disaster in PI Trial
April 3, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…